Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

Literature DB >> 17962760

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

Petr Knesl¹, Dirk Röseling, Ulrich Jordis.

Abstract

The synthesis of three substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib (1), erlotinib (2) and gefitinib (3) in improved yields is reported. The intermediates were characterized by NMR and the purities determined by HPLC.

Entities: Chemical

Mesh：

Substances：

Year: 2006 PMID： 17962760 PMCID： PMC6148630 DOI： 10.3390/11040286

Source DB: PubMed Journal: Molecules ISSN： 1420-3049 Impact factor: 4.411

5 in total

1. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

Authors: Anjali Pandey; Deborah L Volkots; Joseph M Seroogy; Jack W Rose; Jin-Chen Yu; Joseph L Lambing; Athiwat Hutchaleelaha; Stanley J Hollenbach; Keith Abe; Neill A Giese; Robert M Scarborough
Journal: J Med Chem Date: 2002-08-15 Impact factor: 7.446

2. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Authors: Louise M Kelly; Jin-Chen Yu; Christina L Boulton; Mutiah Apatira; Jason Li; Carol M Sullivan; Ifor Williams; Sonia M Amaral; David P Curley; Nicole Duclos; Donna Neuberg; Robert M Scarborough; Anjali Pandey; Stanley Hollenbach; Keith Abe; Nathalie A Lokker; D Gary Gilliland; Neill A Giese
Journal: Cancer Cell Date: 2002-06 Impact factor: 31.743

Review 3. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

Authors: Fortunato Ciardiello; Ferdinando De Vita; Michele Orditura; Sabino De Placido; Giampaolo Tortora
Journal: Expert Opin Emerg Drugs Date: 2003-11 Impact factor: 4.191

Review 4. New cytotoxic and molecular-targeted therapies of head and neck tumors.

Authors: Francesco Caponigro; Franco Ionna; Giuseppe Comella
Journal: Curr Opin Oncol Date: 2004-05 Impact factor: 3.645

5. Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted-pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3' ,5'-phosphate phosphodiesterase inhibitors.

Authors: R H Springer; M B Scholten; D E O'Brien; T Novinson; J P Miller; R K Robins
Journal: J Med Chem Date: 1982-03 Impact factor: 7.446

5 in total

11 in total

1. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Authors: Laura Conradt; Klaus Godl; Christoph Schaab; Andreas Tebbe; Stefan Eser; Sandra Diersch; Christoph W Michalski; Jörg Kleeff; Angelika Schnieke; Roland M Schmid; Dieter Saur; Günter Schneider
Journal: Neoplasia Date: 2011-11 Impact factor: 5.715

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.

1. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

2. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Review 3. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

Review 4. New cytotoxic and molecular-targeted therapies of head and neck tumors.

5. Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted-pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3' ,5'-phosphate phosphodiesterase inhibitors.

1. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

2. Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

3. Methyl 4-(3-chloro-prop-oxy)-5-meth-oxy-2-nitro-benzoate.

4. Methyl 4-(3-chloro-prop-oxy)-3-methoxy-benzoate.

5. N-(4-Isopropoxyphen-yl)acetamide.

6. Methyl 5-meth-oxy-2-nitro-4-[3-(piperidin-1-yl)prop-oxy]benzoate.

7. Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate.

8. Methyl 2-amino-4-(3-chloro-prop-oxy)-5-methoxy-benzoate.

9. Methyl 4-but-oxy-3-methoxy-benzoate.

Review 10. An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles.